Targeting the warburg effect with glucose mutation theory: a two-case study on the efficacy of glucosodiene in treating metastatic triple-positive breast cancer in stage II and IV patients

Abstract

Author(s): Amr Ahmed and Maher Monir. Akl*

This manuscript discusses the significance of Triple-Positive Breast Cancer (Estrogen Receptors Positive (ER+), Progesterone Receptors Positive (PR+), Human Epidermal Growth Factor Receptor 2 (HER2)) TPBC and the aggressive nature of Human Growth Factor Receptor 2 (HER2) in tumor development. The study focuses on the efficacy of Glucosodiene in two distinct cases: a patient with TPBC metastasized to lymph nodes in stage II, another with TPBC spread to lymph nodes, bones, axilla, breasts, peritoneum, and ovaries in stage IV; Results of the PET (Positron Emission Tomography) scan for the first case revealed positive outcomes following Glucosodiene treatment, indicating tumor disappearance and breast vitality restoration. The second case displayed metabolic response. Glucosodiene has shown promise in treating various cancer types, especially metastatic breast cancer, as demonstrated in the first case Triple-Negative Breast Cancer (TNBC) The initial case reported was of a patient suffering from metastatic triple-negative breast cancer to the bones at stage two, and her recovery was documented within 15 days of starting treatment. This case spurred further research into the use of Glucosodiene in various conditions. Promising results emerged, including the previously mentioned case and the two other cases in this study, suggesting that Glucosodiene targets different types of breast cancer receptors. The therapy targets tumor metabolic activity, based on the Glucose Mutation Theory pioneered by Maher Akl, offering a novel and effective treatment approach.

Share this article